Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Trimethylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL27829687 | 0.98 | GAA (0.52) | GAALMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL6917582 | 0.95 | GAA (0.59) | GAALMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL29991938 | 0.93 | GAA (0.62) | GAALMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1705904 | 0.93 | GAA (0.62) | GAALMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL31313 | 0.93 | GAA (0.62) | GAALMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL5068661 | 0.93 | GAA (0.62) | GAALMNASMN1; SMN2MAPTALDH1A1 | |
| P-Xylene SCHEMBL8660591 | 0.93 | GAA (0.62) | GAALMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL11432043 | 0.93 | GAA (0.62) | GAALMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL34 | 0.93 | GAA (0.62) | GAALMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3180429 | 0.90 | GAA (0.59) | GAALMNASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3755663-A1 | METHOD FOR DECONTAMINATING AN AQUEOUS LIQUID MEDIUM CONTAINING MICROPOLLUTANTS OR A SURFACE CONTAMINATED WITH MICROPOLLUTANTS | UNIVERSITE DE BORDEAUX (FR) | 2020-12-30 | — | — | EP | claimed |
| EP-3178813-A1 | METHOD FOR PREPARING HALOGENATED 3-OXOCARBOXYLATES CARRYING A 2-ALKOXYMETHYLIDENE OR A 2-DIALKYLAMINOMETHYLIDENE GROUP | BASF SE (DE) | 2017-06-14 | — | — | EP | claimed |
| US-5118836-A | OPTICALLY ACTIVE FLUORINE-CONTAINING 3-HYDROXYBUTYRIC ACID ESTERS AND PROCESS FOR PRODUCING THE SAME | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1992-06-02 | — | — | US | claimed |
| EP-4634388-A1 | COMPOSITIONS AND METHODS FOR INFECTIOUS DISEASES | Providence Therapeutics Holdings Inc. (CA) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025061153-A1 | RNA-LIPID PARTICLES COMPRISING POLYSARCOSINE-LIPID CONJUGATE | Everest Medicines (China) Co., Ltd. (CN) | 2025-03-27 | — | — | WO | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4452928-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4402123-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-118317944-A | Acyclic lipids and methods of use thereof | 雷纳嘉德医疗管理公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118234707-A | Cyclic lipids and methods of use thereof | 雷纳嘉德医疗管理公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-0227358-B1 | HOUSING PACK FOR PHOTOGRAPHIC PROCESSING SOLUTION | KONICA CORPORATION (JP) | 1992-08-12 | — | — | EP | disclosed |
| US-5118836-A | OPTICALLY ACTIVE FLUORINE-CONTAINING 3-HYDROXYBUTYRIC ACID ESTERS AND PROCESS FOR PRODUCING THE SAME | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1992-06-02 | — | — | US | disclosed |
| EP-0168224-B1 | POSITIVELY CHARGED COLORED TONER COMPOSITIONS | XEROX CORPORATION (US) | 1992-03-11 | — | — | EP | disclosed |
| EP-0427396-A2 | Process for producing optically active fluorine-containing 3-hydroxybutyric acid esters | Showa Shell Sekiyu Kabushiki Kaisha (JP) | 1991-05-15 | — | — | EP | disclosed |
| EP-0331266-A1 | Coating composition | NIPPON PAINT CO., LTD. (JP) | 1989-09-06 | — | — | EP | disclosed |
| US-4791013-A | STORAGE AND WASTE COMPARTMENTS; OXYGEN BARRIER MEMBRANE | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1988-12-13 | — | — | US | disclosed |
| EP-0168224-A2 | Positively charged colored toner compositions | XEROX CORPORATION (US) | 1986-01-15 | — | — | EP | disclosed |
| US-4562135-A | DYE CHARGE CONTROL COMPOSITION COMPRISING A CHROIMOPHORE MOLECULE AND A TRIBOELECTRIC CHARGE ESTABLISHING GROUP | XEROX CORPORATION (US) | 1985-12-31 | — | — | US | disclosed |
| US-4079174-A | WATER SOLUBLE ONIUM SALTS IN ELECTROLYTE | BASF AKTIENGESELLSCHAFT (DT) | 1978-03-14 | — | — | US | disclosed |